Furazolidone

Identification

Summary

Furazolidone is a drug for the treatment of infectious diarrhea.

Generic Name

Furazolidone

DrugBank Accession Number

DB00614

Background

A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)

Type

Small Molecule

Groups

Experimental, Vet approved

Structure

Similar Structures

Weight: Average: 225.16
Monoisotopic: 225.038570337
Chemical Formula: C₈H₇N₃O₅

Synonyms

3-(5'-Nitrofurfuralamino)-2-oxazolidone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone
3-[(5-Nitrofurylidene)amino]-2-oxazolidone
3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
Furazolidona
Furazolidone
Furazolidonum
FZL
N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone
N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one
Nitrofurazolidone
Nitrofurazolidonum

External IDs

USAF EA-1

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Treatment of	Dysentery		••••••••••••			••••••
Treatment of	Infectious diarrhea		••••••••••••			••••••

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.

Mechanism of action

Furazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.

Target	Actions	Organism
ADNA	cross-linking/alkylation	Humans

Absorption

Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.

Hover over products below to view reaction partners

Furazolidone
- beta-Hydroxyethylhydrazine
- 3-amino-2-oxazolidone

Route of elimination

Not Available

Half-life

10 minutes

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when Furazolidone is combined with 1,2-Benzodiazepine.
Abaloparatide	Furazolidone may increase the orthostatic hypotensive activities of Abaloparatide.
Abciximab	The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Abciximab.
Acarbose	Furazolidone may increase the hypoglycemic activities of Acarbose.
Acebutolol	Furazolidone may increase the hypotensive activities of Acebutolol.

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Dependal-M (GlaxoSmithKline) / Furoxone (Roberts Laboratories)

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
ฟูราเซี่ยน ชนิดแขวนตะกอน	Furazolidone (50 MG/15ML) + Kaolin (3 G/15ML) + Pectin (150 MG/15ML)	Suspension	Oral	บริษัท เอเชี่ยน ฟาร์มาซูติคัล จำกัด	1984-11-04	2020-07-19
ฟูลิน	Furazolidone (50 MG/15ML) + Kaolin (3 G/15ML) + Pectin (225 MG/15ML)	Suspension	Oral	บริษัท เอเชี่ยนยูเนี่ยนแล็บบอราตอรี่ จำกัด จำกัด	1988-02-17	2020-07-19
ยาน้ำฟูโรปีน	Furazolidone (50 MG/15ML) + Kaolin (3 G/15ML) + Pectin (150 MG/15ML)	Suspension	Oral	บริษัท บี.เอม.ฟาร์มาซี จำกัด	1985-11-20	2020-07-19
แบคซีลา เม็ด	Furazolidone (50 mg) + Diiodohydroxyquinoline (250 mg) + Neomycin sulfate (50 mg) + Succinylsulfathiazole (250 mg)	Tablet		บริษัท ไบร์วู๊ดฟาร์มาซูติคอล จำกัด	1986-03-07	2020-07-19
โปรฟูร่า ซัสเพนชั่น	Furazolidone (50 mg/15mL) + Kaolin (3 g/15mL) + Pectin (75 mg/15mL)	Suspension	Oral	บริษัท เมดิซีน โปรดักส์ จำกัด	1989-06-06	Not applicable

Chemical Identifiers

UNII: 5J9CPU3RE0
CAS number: 67-45-8
InChI Key: PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI: InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
IUPAC Name: 3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
SMILES: [O-][N+](=O)C1=CC=C(O1)\C=N\N1CCOC1=O

References

Synthesis Reference

Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.

US2742462

General References

Not Available

External Links

Human Metabolome Database: HMDB0014752
KEGG Drug: D00830
KEGG Compound: C07999
PubChem Compound: 3435
PubChem Substance: 46507291
ChemSpider: 4481255
RxNav: 4601
ChEBI: 5195
ChEMBL: CHEMBL1103
ZINC: ZINC000000113418
Therapeutic Targets Database: DAP000993
PharmGKB: PA164746760
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Furazolidone

MSDS

Download (74.1 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Duodenal Ulcer Due to Helicobacter Pylori	1
4	Completed	Treatment	Dyspepsia / Gastric Cancer / Gastritis / Helicobacter Pylori Infection / Peptic Ulcer	1
4	Completed	Treatment	Functional Dyspepsia / Scarred Peptic Ulcer	1
4	Completed	Treatment	Gastric Cancer / Gastric Ulcer / Gastritis / Gastritis Chronic / Helicobacter Pylori Infection	1
4	Completed	Treatment	Helicobacter Pylori	1

Pharmacoeconomics

Manufacturers

Shire development inc

Packagers

Professional Co.

Dosage Forms

Form	Route	Strength
Suspension	Oral	333.3 mg
Suspension	Oral	33330000 mg
Tablet	Oral	0.1 g
Tablet, coated	Oral	100 mg
Suspension	Oral	0.333 g
Suspension	Oral	0.3333 g
Suspension	Oral	333.33 mg
Suspension	Oral	150 ml
Suspension	Oral	30 mg
Tablet	Oral
Suspension	Oral	1 g
Tablet	Oral	200 mg
Suspension	Oral	0.5 g
Suspension	Oral
Suspension	Oral
Tablet	Oral	100 mg
Tablet

Prices

Unit description	Cost	Unit
Furazolidone powder	2.04USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	254-256	Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company
water solubility	40 mg/L (at 25 °C)	MERCK INDEX (1996); pH 6
logP	-0.04	DEBNATH,AK ET AL. (1991)

Predicted Properties

Property	Value	Source
Water Solubility	0.364 mg/mL	ALOGPS
logP	0.15	ALOGPS
logP	0.87	Chemaxon
logS	-2.8	ALOGPS
pKa (Strongest Basic)	-2.4	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	98.18 Å²	Chemaxon
Rotatable Bond Count	3	Chemaxon
Refractivity	50.08 m³·mol^-1	Chemaxon
Polarizability	19.78 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9038
Blood Brain Barrier	+	0.9117
Caco-2 permeable	-	0.5736
P-glycoprotein substrate	Non-substrate	0.7829
P-glycoprotein inhibitor I	Non-inhibitor	0.7761
P-glycoprotein inhibitor II	Non-inhibitor	0.9597
Renal organic cation transporter	Non-inhibitor	0.8351
CYP450 2C9 substrate	Non-substrate	0.8117
CYP450 2D6 substrate	Non-substrate	0.8415
CYP450 3A4 substrate	Substrate	0.5984
CYP450 1A2 substrate	Inhibitor	0.9107
CYP450 2C9 inhibitor	Non-inhibitor	0.907
CYP450 2D6 inhibitor	Non-inhibitor	0.9134
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.928
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8828
Ames test	AMES toxic	0.9108
Carcinogenicity	Non-carcinogens	0.9097
Biodegradation	Ready biodegradable	0.8978
Rat acute toxicity	2.1639 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7889
hERG inhibition (predictor II)	Non-inhibitor	0.9057

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	154.5175672	predicted	DarkChem Lite v0.1.0
[M-H]-	154.5704672	predicted	DarkChem Lite v0.1.0
[M-H]-	154.5694672	predicted	DarkChem Lite v0.1.0
[M-H]-	143.01942	predicted	DeepCCS 1.0 (2019)
[M+H]+	154.2529672	predicted	DarkChem Lite v0.1.0
[M+H]+	159.1149741	predicted	DarkChem Lite v0.1.0
[M+H]+	154.2312672	predicted	DarkChem Lite v0.1.0
[M+H]+	145.12224	predicted	DeepCCS 1.0 (2019)
[M+Na]+	155.2195672	predicted	DarkChem Lite v0.1.0
[M+Na]+	159.6175257	predicted	DarkChem Lite v0.1.0
[M+Na]+	155.1735672	predicted	DarkChem Lite v0.1.0
[M+Na]+	151.03389	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. DNA

Kind

Nucleotide

Organism

Humans

Pharmacological action

Yes

Actions

Cross-linking/alkylation

DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Meng J, Mangat SS, Grudzinski IP, Law FC: Evidence of 14C-furazolidone metabolite binding to the hepatic DNA of trout. Drug Metabol Drug Interact. 1998;14(4):209-19. [Article]

Enzymes

Details1. Amine oxidase [flavin-containing] A

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Serotonin binding
Specific Function: Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name: MAOA
Uniprot ID: P21397
Uniprot Name: Amine oxidase [flavin-containing] A
Molecular Weight: 59681.27 Da

References

Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [Article]
Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [Article]
Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [Article]

Details2. Amine oxidase [flavin-containing] B

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Primary amine oxidase activity
Specific Function: Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name: MAOB
Uniprot ID: P27338
Uniprot Name: Amine oxidase [flavin-containing] B
Molecular Weight: 58762.475 Da

References

Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67. [Article]
Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60. [Article]
Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91. [Article]

Drug created at June 13, 2005 13:24 / Updated at December 02, 2023 06:53

Furazolidone

Identification

Structure for Furazolidone (DB00614)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)

Targets

References

Enzymes

References

References